Neogenomics Laboratories

NeoGenomics News

NeoGenomics Hurricane Ian Emergency Response

Important Announcement

Dear Valued Client,

Over the last week, we have closely monitored Hurricane Ian as it enters the Gulf of Mexico and is making landfall on the southwest coast of Florida as a Category 4 hurricane. We have established a Hurricane Ian Emergency Response Team to focus all our efforts on business continuity for our Fort Myers and Tampa, Florida facilities.

Our number one priority is patient care. We have been working around the clock for several days and have focused our efforts to ensure patient samples that would be performed in Florida are performed elsewhere within our extensive network across the country and that turnaround time delays are minimized.

Simultaneously, we have activated a plan to support the safety and well-being of our NeoGenomics employees and their families.

Communication is a critical component of our emergency response plan and over the next several days and weeks, you can expect regular updates.

As of today, here is what you should know:

·         Logistics: We have taken steps to re-route inbound Florida samples.

·         Staffing: We have re-directed all resources to our other clinical labs within our network to prioritize in-bound clinical samples, including re-allocating technical staff from our pharma services division.

·         Fort Myers, FL Headquarters: Our Fort Myers HQ is designed to withstand a Category 5 Hurricane and we are ready re-start operations once our FedEx and courier teams can resume services and our employees can safely return to this facility.

·         Resource allocation: We have allocated all resources to the Hurricane Ian Emergency Response Team and will spare no expense to ensure our patients and employees come first as we navigate thru this storm.

On a personal note, I am humbled, inspired and so incredibly proud of our Neo family, as they bring to life our Mission to “save lives by improving patient care.” Our values of Teamwork, Quality and Accountability are shining through during this difficult time.

If you have any questions, please feel free to contact our Client Services team at (877) 776-5907.

Warmest regards,

Chris Smith,

Chief Executive Officer

NeoGenomics Laboratories


Test Updates


CMV ISH - Effective Monday, October 10th, CMV ISH will return to our testing menu and be available for ordering. CMV ISH is useful for detection of primary, latent, and reactivated CMV infections in FFPE tissues. Please Note: For clients ordering using paper requisitions, please write-in this test order, as the requisitions will not yet reflect this offering.

  • CPT: 88365 x 1
  • Level of Service: Global


Level of Service Displayed in Online Orders and Interfaced Orders - Effective Monday, October 10th, Online Orders 1.0, 2.0, and Interfaced Orders will be updated to accurately reflect the Level of Service offerings for our Technical IHC and ISH tests. For the most current listing of our test offerings and service levels, please refer to our online test menu.


The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.


Special Announcements

RET fusions are now approved targets in all solid tumor types

Last week the FDA issued the first approval of a RET-fusion targeted therapy for use against all types of solid tumor. Details are available here.

NeoGenomics provides options for highly sensitive RNA-based NGS detection of RET fusions. NTRK & RET NGS Fusion Panel is a compact pan-tumor test, while the Targeted Solid Tumor NGS Fusion Panel covers 19 genes most relevant to fusion-targeted therapies and clinical trial options. Please contact your NeoGenomics Sales Consultant for additional NGS and FISH test options.


Interface Updates

For interface-related test changes that are taking effect on Monday October 9th, click here for a downloadable document to view the impacted interface test codes. Several Histology test codes will be discontinued.

If you have interface questions, please contact